abstract: BACKGROUND AND AIMS: Previous studies mostly focused on the diagnostic accuracy of @entity358 ( @entity358 ) in the diagnosis of @entity401 ( @entity401 ). We aimed to explore the clinical usefulness of @entity358 results in the diagnostic procedure of undefined @entity401 . METHODS: The retrospective analysis included @entity1 undergoing @entity358 for the diagnosis of undefined @entity401 from January 2007 to December 2010. The clinically useful @entity358 was defined as that lead to a specific histopathological diagnosis or that was consistent with the working diagnosis based on existing clinical and radiological data. RESULTS: A total of 664 @entity1 were included in the study. @entity358 failed to obtain lung parenchyma in 155 cases (23.3%). @entity358 was considered clinically helpful in 202 procedures (30.4%), including 114 cases that provided definitive histopathological diagnoses and 88 cases that were consistent with working diagnoses. Among 202 cases of clinically useful TBLBs, the majority were diagnosed as @entity5970 ( @entity5970 ) (67 cases, 33.2%), connective tissue disease-related @entity401 (CTD- @entity401 ) (65, 32.2%) and @entity2416 ( @entity2416 ) (33, 16.3%). Although @entity358 could provide definitive histopathological diagnoses in all cases diagnosed as @entity5970 , only few cases of @entity2416 (7, 21.2% of @entity2416 diagnoses) and CTD- @entity401 (9, 13.8% of CTD-ILD diagnoses) could be identified by TBLBs. CONCLUSION: The clinical usefulness of @entity358 , in conjunction with thorough clinical and radiological data, in the diagnosis of @entity401 may be varied depending on different subtypes. The use of histopathological analysis and the type of biopsy employed should therefore be considered on a case-by-case basis.

title: The evaluation of clinical usefulness of transbrochoscopic lung biopsy in undefined XXXX : a retrospective study.

entities_list: @entity2416 :: ('MESH:D054990', 'Disease') :: ['IPF', 'idiopathic pulmonary fibrosis']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['TBLB', 'transbronchoscopic lung biopsy']

entities_list: @entity5970 :: ('MESH:D011649', 'Disease') :: ['pulmonary alveolar proteinosis', 'PAP']

entities_list: @entity401 :: ('MESH:D017563', 'Disease') :: ['ILDs', 'interstitial lung diseases']

answer: @entity401 :: (MESH:D017563,Disease) :: ['interstitial lung diseases']


abstract: @entity13983 (EA) has been shown to have antioxidant, antibacterial, and anti-inflammatory activities. In Uighur traditional medicine, Euphorbia humifusa Willd is used to treat @entity364 , and recent studies suggest that it is the EA content which is responsible for its therapeutic effect. However, the effects of EA on antifungal activity have not yet been reported. This study aimed to investigate the inhibitory effect of EA on fungal strains both in vitro and in vivo. The minimal inhibitory concentration (MIC) was determined by the National Committee for Clinical Laboratory Standards (M38-A and M27-A2) standard method in vitro. EA had a broad spectrum of antifungal activity, with MICs for all the tested dermatophyte strains between 18.75 and 58.33     g/ml. EA was also active against two Candida strains, with MICs between 25.0 and 75.0     g/ml. It was inactive against @entity7408 . The susceptibility of six species of dermatophytes to EA was comparable with that of the commercial antifungal, @entity2380 . The most sensitive filamentous species was @entity12734 (MIC   =   18.75     g/ml). Studies on the mechanism of action using an HPLC-based assay and an enzyme linked immunosorbent assay showed that EA inhibited @entity12364 biosynthesis and reduced the activity of @entity5068 14a-demethylase P450 (CYP51) in the @entity12734 membrane, respectively. An in vivo test demonstrated that topical administration of EA (4.0 and 8.0   mg/cm(2) ) significantly enhanced the cure rate in a @entity840 @entity281 model of @entity12734 . The results suggest that EA has the potential to be developed as a natural antifungal agent.

title: Antifungal Activity of XXXX In Vitro and In Vivo.

entities_list: @entity12364 :: ('MESH:D004875', 'Chemical') :: ['ergosterol']

entities_list: @entity2380 :: ('MESH:D015725', 'Chemical') :: ['fluconazole']

entities_list: @entity7408 :: ('5478', 'Species') :: ['Candida glabrata']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity364 :: ('MESH:D009181', 'Disease') :: ['fungal diseases']

entities_list: @entity13983 :: ('MESH:D004610', 'Chemical') :: ['Ellagic acid']

entities_list: @entity12734 :: ('5551', 'Species') :: ['Trichophyton rubrum']

answer: @entity13983 :: (MESH:D004610,Chemical) :: ['Ellagic Acid']


abstract: INTRODUCTION: The aim of the present study was to evaluate the role of intravenous @entity619 in relieving the symptoms and signs of @entity388 in the emergency department setting. @entity1 AND METHODS: This was a randomized, placebo-controlled, superiority, single-blind study. @entity1 were randomized either to intravenous @entity619 (group A) or to placebo (group B), with all @entity1 receiving symptomatic therapy. The primary outcome was defined as necessity to hospitalize @entity1 who present with @entity388 in the emergency department. The secondary outcomes were (a) improvement in nystagmus, (b) improvement in postural instability, (c) lessening of @entity390 , (d) @entity391 , and (e) recovery of subjective symptoms. RESULTS: Altogether, 100 @entity1 were randomized, 51 into group A and 49 into group B. There was no difference in the hospitalization rate between groups (P=0.284). In both groups, there was a statistically significant difference in the values of all measured variables 2   h after therapy intervention compared with the baseline values. In group A, significantly fewer @entity1 had third-degree nystagmus 2   h after therapy intervention whereas the difference in group B did not reach statistical significance. After therapy, more @entity1 had first-degree nystagmus in group A as well as in group B than before the intervention. There was a significantly greater absolute difference in European Evaluation of Vertigo scale results in group A compared with group B. CONCLUSION: The value of @entity619 cannot be established, given the small sample and limitations of the present study. Some observations consistent with clinical improvement cannot exclude a true treatment effect, and further study is still warranted.

title: Intravenous @entity619 in acute management of XXXX : a randomized, placebo-controlled, single-blind trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['lessening of vomiting']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity388 :: ('MESH:D020338', 'Disease') :: ['vestibular neuritis']

answer: @entity388 :: (MESH:D020338,Disease) :: ['vestibular neuritis']


abstract: INTRODUCTION: The aim of the present study was to evaluate the role of intravenous @entity619 in relieving the symptoms and signs of @entity388 in the emergency department setting. @entity1 AND METHODS: This was a randomized, placebo-controlled, superiority, single-blind study. @entity1 were randomized either to intravenous @entity619 (group A) or to placebo (group B), with all @entity1 receiving symptomatic therapy. The primary outcome was defined as necessity to hospitalize @entity1 who present with @entity388 in the emergency department. The secondary outcomes were (a) improvement in nystagmus, (b) improvement in postural instability, (c) lessening of @entity390 , (d) @entity391 , and (e) recovery of subjective symptoms. RESULTS: Altogether, 100 @entity1 were randomized, 51 into group A and 49 into group B. There was no difference in the hospitalization rate between groups (P=0.284). In both groups, there was a statistically significant difference in the values of all measured variables 2   h after therapy intervention compared with the baseline values. In group A, significantly fewer @entity1 had third-degree nystagmus 2   h after therapy intervention whereas the difference in group B did not reach statistical significance. After therapy, more @entity1 had first-degree nystagmus in group A as well as in group B than before the intervention. There was a significantly greater absolute difference in European Evaluation of Vertigo scale results in group A compared with group B. CONCLUSION: The value of @entity619 cannot be established, given the small sample and limitations of the present study. Some observations consistent with clinical improvement cannot exclude a true treatment effect, and further study is still warranted.

title: Intravenous XXXX in acute management of @entity388 : a randomized, placebo-controlled, single-blind trial.

answer: @entity619 :: (MESH:D003907,Chemical) :: ['dexamethasone']


abstract: Because of the involvement of prostaglandins in the labor mechanism, it was hypothesized that elevated @entity3009 levels would presage preterm deliveries. A comparison of plasma @entity18314 ( @entity22775 ) levels was made between pregnant @entity1 who eventually delivered at term (N = 22) and those who delivered preterm (N = 17). Maternal blood was collected from each @entity1 at approximately 1-week intervals between 16 and 40 weeks' gestation and during labor. Mixed cord blood was also obtained at delivery. @entity22775 was measured in plasma by radioimmunoassay. Plasma @entity22775 concentrations did not vary throughout pregnancy. @entity22775 concentrations did increase during labor, and the highest levels were found in cord blood at delivery. Mean @entity22775 levels during labor and in cord blood were not significantly different between the preterm and term groups. In 1 @entity3152 @entity1 the @entity22775 concentration during labor was higher than that of all other @entity1 , including those who delivered at term. Excluding this @entity1 , @entity3152 @entity22775 concentrations were significantly lower (P less than .05) than those at term. In general, the study provides evidence that most cases of @entity3152 are not characterized by elevated @entity3009 levels.

title: Plasma XXXX in pregnant @entity1 with term and preterm deliveries.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity18314 :: ('MESH:C008228', 'Chemical') :: ['13,14-dihydro-15-ketoprostaglandin F2 alpha']

entities_list: @entity3152 :: ('MESH:D007752', 'Disease') :: ['preterm delivery', 'preterm labor']

entities_list: @entity3009 :: ('CHEBI:26333', 'Chemical') :: ['prostaglandin']

answer: @entity3009 :: (CHEBI:26333,Chemical) :: ['prostaglandin']


abstract: Because of the involvement of prostaglandins in the labor mechanism, it was hypothesized that elevated @entity3009 levels would presage preterm deliveries. A comparison of plasma @entity18314 ( @entity22775 ) levels was made between pregnant @entity1 who eventually delivered at term (N = 22) and those who delivered preterm (N = 17). Maternal blood was collected from each @entity1 at approximately 1-week intervals between 16 and 40 weeks' gestation and during labor. Mixed cord blood was also obtained at delivery. @entity22775 was measured in plasma by radioimmunoassay. Plasma @entity22775 concentrations did not vary throughout pregnancy. @entity22775 concentrations did increase during labor, and the highest levels were found in cord blood at delivery. Mean @entity22775 levels during labor and in cord blood were not significantly different between the preterm and term groups. In 1 @entity3152 @entity1 the @entity22775 concentration during labor was higher than that of all other @entity1 , including those who delivered at term. Excluding this @entity1 , @entity3152 @entity22775 concentrations were significantly lower (P less than .05) than those at term. In general, the study provides evidence that most cases of @entity3152 are not characterized by elevated @entity3009 levels.

title: Plasma @entity3009 in pregnant XXXX with term and preterm deliveries.

answer: @entity1 :: (9606,Species) :: ['women']


abstract: OBJECTIVES: The purpose of this study was to describe rates and patterns of long- and short-acting alpha agonist use for @entity146 in a primary care population following Food and Drug Administration (FDA) approval of the long-acting alpha agonists @entity1774 and @entity1338 . METHODS: @entity1 and adolescents 4-18 years of age, who received an alpha agonist prescription between 2009 and 2011, were identified from a sample of 45 United States primary care practices in two electronic health record-based research networks. Alpha agonist receipt was identified using National Drug Codes and medication names. The proportion of subjects receiving long- and short-acting prescriptions in each year was calculated and examined with respect to reported mental health diagnoses, and whether indications for use were on-label, had evidence from clinical trials, or had no trial evidence. RESULTS: In a cohort of 282,875 subjects, 27,671 (10%) received any psychotropic medication and only 4,227 subjects (1.5%) received at least one prescription for an alpha agonist, most commonly a short-acting formulation (83%). Only 20% of alpha agonist use was on-label (use of long-acting formulations for @entity71 [ @entity71 ]). Most subjects (68%) received alpha agonists for indications with evidence of efficacy from clinical trials but no FDA approval, primarily short-acting formulations for @entity71 and @entity2438 ; 12% received alpha agonists for diagnoses lacking randomized clinical trial evidence in @entity1 , including @entity25 and @entity148 , or for which there was no documented mental health diagnosis. Rates of long-acting alpha agonist use increased more than 20-fold from 0.2% to 4%, whereas rates of short-acting alpha agonist use grew only slightly between 2009 and 2011 from 10.6% to 11.3%. CONCLUSIONS: Alpha agonist use was uncommon in this population, and most subjects received short-acting forms for conditions that were off-label, but with clinical trial evidence. The safety and efficacy of use for conditions, including @entity25 and @entity148 , lacking evidence from randomized trials, warrant further investigation.

title: Changing patterns of alpha agonist medication use in XXXX and adolescents 2009-2011.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Children']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['behavioral problems']

entities_list: @entity71 :: ('MESH:D001289', 'Disease') :: ['ADHD', 'attention-deficit/hyperactivity disorder']

entities_list: @entity1338 :: ('MESH:D003000', 'Chemical') :: ['clonidine']

entities_list: @entity1774 :: ('MESH:D016316', 'Chemical') :: ['guanfacine']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep disorders']

answer: @entity1 :: (9606,Species) :: ['children']


abstract: BACKGROUND: Collaboration between family caregivers and health professionals in specialised hospitals or community-based primary healthcare systems can be challenging. During the course of severe @entity102 , several health professionals might be involved at a given time, and the @entity1 's illness may be unpredictable or not well understood by some of those involved in the treatment and care. AIM: The aim of this study was to explore the experiences and expectations of family caregivers for @entity1 with @entity2033 concerning collaboration with healthcare professionals. METHODS: To shed light on collaboration from the perspectives of family caregivers, we conducted an explorative, qualitative interview study with 15 adult @entity1 experienced from caring for family members in all stages of @entity2033 . Data were analysed with systematic text condensation, a cross-case method for thematic analysis of qualitative data. RESULTS: We found that family caregivers approached health services hoping to understand the illness course and to share their concerns and stories with skilled and trustworthy professionals. Family caregivers felt their involvement in consultations and access to ongoing exchanges of knowledge were important factors in improved health services. They also felt that the clarity of roles and responsibilities was crucial to collaboration. CONCLUSIONS: Family caregivers should be acknowledged for their competences and should be involved as contributors in partnerships with healthcare professionals. Our study suggests that building respectful partnerships with family caregivers and facilitating the mutual sharing of knowledge may improve the coordination of care. It is important to establish clarity of roles adjusted to caregivers' individual resources for managing responsibilities in the care process.

title: Family caregivers' views on coordination of care in XXXX : a qualitative study.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patient', 'persons']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic disease']

entities_list: @entity2033 :: ('MESH:D006816', 'Disease') :: ["Huntington's disease"]

answer: @entity2033 :: (MESH:D006816,Disease) :: ['Huntington's disease']


abstract: BACKGROUND AND OBJECTIVES: Identification of mutations in the downstream @entity470 ( @entity470 ) signaling pathway could provide important insights of @entity470 -targeted therapies in @entity14 . We analyzed the mutation spectra of the @entity10412 / @entity983 / @entity584 and RAS/ @entity8496 /MAPK pathways in @entity14 and the associations of these mutations with sites of @entity3 or recurrence. METHODS: The study population comprised 1,492 retrospectively collected stages I-IV @entity14 specimens. Tissue was obtained between 2000 and 2010 at a single hospital. We analyzed 61 hot spots using MALDI-TOF mass spectrometry for nucleic acid analysis. RESULTS: Mutations were found in the RAS pathway in 47.3% of @entity1 and in the @entity10412 pathway in 14.3% of @entity1 , with 9.2% of @entity1 carrying mutations in both pathways. Both the RAS and @entity10412 pathway mutations were significantly associated with proximal @entity5 , @entity5 , and microsatellite instability. @entity5 carrying a RAS pathway mutation exhibited a higher frequency of lung and peritoneal @entity3 than did @entity5 with a wild-type gene (P   =   0.025 and 0.009, respectively). @entity8497 gene mutation was significantly associated with lung @entity3 (P   =   0.001). CONCLUSIONS: Somatic mutations in the RAS pathway of the @entity5 in @entity14 can influence patterns of @entity3 and recurrence.

title: Mutations in the RAS and @entity10412 pathways are associated with metastatic location in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['mucinous tumors', 'Tumors', 'primary tumor', 'tumors']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancers', 'colorectal cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'metastases']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal cancers']


abstract: BACKGROUND AND OBJECTIVES: Identification of mutations in the downstream @entity470 ( @entity470 ) signaling pathway could provide important insights of @entity470 -targeted therapies in @entity14 . We analyzed the mutation spectra of the @entity10412 / @entity983 / @entity584 and RAS/ @entity8496 /MAPK pathways in @entity14 and the associations of these mutations with sites of @entity3 or recurrence. METHODS: The study population comprised 1,492 retrospectively collected stages I-IV @entity14 specimens. Tissue was obtained between 2000 and 2010 at a single hospital. We analyzed 61 hot spots using MALDI-TOF mass spectrometry for nucleic acid analysis. RESULTS: Mutations were found in the RAS pathway in 47.3% of @entity1 and in the @entity10412 pathway in 14.3% of @entity1 , with 9.2% of @entity1 carrying mutations in both pathways. Both the RAS and @entity10412 pathway mutations were significantly associated with proximal @entity5 , @entity5 , and microsatellite instability. @entity5 carrying a RAS pathway mutation exhibited a higher frequency of lung and peritoneal @entity3 than did @entity5 with a wild-type gene (P   =   0.025 and 0.009, respectively). @entity8497 gene mutation was significantly associated with lung @entity3 (P   =   0.001). CONCLUSIONS: Somatic mutations in the RAS pathway of the @entity5 in @entity14 can influence patterns of @entity3 and recurrence.

title: Mutations in the RAS and XXXX pathways are associated with metastatic location in @entity14 .

answer: @entity10412 :: (5293,Gene) :: ['PI3K']


abstract: INTRODUCTION: Poststroke, less-severe motor impairment occurs on the ipsilesional side of body. The objective of the present study was to evaluate the effectiveness of the motor training involving the less-affected side (MTLA) in @entity64 . METHODS: This was a randomized, controlled, double-blinded pilot study conducted in the occupational therapy unit of a rehabilitation Institute. A convenience sample of 35 @entity64 subjects (mean poststroke duration, 28.76 weeks) was randomized into two groups (the experimental group: 17 and control group: 18). Thirty-two @entity1 completed the entire study protocol. The experimental group and control group were provided MTLA and neurophysiological-based conventional therapy respectively. Both the groups received 24 treatment sessions (60 minutes each) over the period of two months. The Affected side was assessed using Brunnstrom recovery stage ( @entity4375 ) and Fugl-Meyer assessment (FMA) whereas the less-affected side was evaluated by Minnesota manual dexterity test (MMDT), Purdue peg board test (PPBT) and Manual Muscle Testing (MMT). RESULTS: Postintervention, the less-affected side of experimental group demonstrated significant improvement for MMDT (P = 0.003), PPBT (P = 0.01) and MMT (P   <    0.001 to 0.043) in comparison to the control group. Further, as compared to the control group, the experimental group exhibited positive significant change for the measure of affected side [ @entity4375 (P <    0.001) and FMA (P <    0.001 to 0.03)] at post assessment. CONCLUSION: MTLA enhanced the muscle strength, dexterity and coordination of the less-affected side as well as the motor recovery of the affected side in poststroke hemiparetic subjects.

title: Effect of motor training involving the less-affected side (MTLA) in post- XXXX subjects: a pilot randomized controlled trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants']

answer: @entity64 :: (MESH:D020521,Disease) :: ['stroke']


abstract: A prospective study of an Intracath method of diagnostic peritoneal lavage was done of 100 @entity1 with blunt @entity1661 . Initial results in @entity235 confirmed the reliability and sensitivity of the technique. In @entity1 , it proved to be 96 per cent accurate. Fifty-eight @entity1 had true-positive results, and in 52 of these, subsequent laparotomy demonstrated significant hemoperitoneum and intra-abdominal injury. Six @entity1 had intra-abdominal injuries of limited significance. Thirty-eight of these @entity1 were considered to have true-negative results. In one @entity1 , false-negative, signs of @entity548 later developed, and a splenectomy was performed without incidence. There were three false-positive results. These @entity1 underwent laparotomy and recovered without a problem. The only complications noted were puncture of the urinary bladder in one @entity1 and subcutaneous infusions of lavage fluid in two @entity1 which were recognized during the procedure. Results of this study demonstrate the safety and reliability of the Intracath method of peritoneal lavage for @entity1 with blunt @entity1661 .

title: Peritoneal lavage in blunt XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1661 :: ('MESH:D000008', 'Disease') :: ['abdominal trauma']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['intra-abdominal bleeding']

answer: @entity1661 :: (MESH:D000008,Disease) :: ['abdominal trauma']


abstract: BACKGROUND: @entity4093 ( @entity4093 ) and @entity11935 ( @entity11935 ) are @entity2125 -dependent protein deacetylases involved in the regulation of key @entity5 -associated genes. In this study we evaluated the relevance of these deacetylases in @entity2 biology. MATERIAL AND METHODS: Protein levels of @entity4093 and @entity11935 were determined in @entity1149 ( @entity1149 ) cell lines and @entity5 from 105 @entity1 . Changes in proliferation were assessed after @entity4093 and @entity11935 downregulation in @entity2 cell lines using siRNA-mediated technology or tenovin-1, a @entity4093 and @entity11935 inhibitor. RESULTS: High @entity4093 and @entity11935 protein levels were found in @entity1149 cell lines compared with non-tumor lung epithelial cells. The expression of @entity4093 and @entity11935 proteins was also significantly higher in lung @entity5 than in normal tissue (P<0.001 for both sirtuins). Stronger nuclear @entity4093 staining was observed in @entity420 than in @entity957 (P=0.033). Interestingly, in @entity1149 @entity1 , high @entity4093 and @entity11935 expression levels were associated with shorter recurrence-free survival (P=0.04 and P=0.007, respectively). Moreover, the combination of high @entity4093 and @entity11935 expression was an independent prognostic factor for shorter recurrence-free survival (P=0.002) and overall survival (P=0.022). In vitro studies showed that @entity4093 and/or @entity11935 downregulation significantly decreased proliferation of @entity1149 . CONCLUSIONS: Our results support the hypothesis that @entity4093 and @entity11935 have a protumorigenic role in @entity2 , promoting cell proliferation. Moreover, the expression of these proteins is associated with poor prognosis in @entity1149 @entity1 and may help to identify those @entity1149 @entity1 with high risk of recurrence that could benefit from adjuvant therapy after resection.

title: Expression of sirtuin 1 and 2 is associated with poor prognosis in XXXX @entity1 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumors', 'cancer']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinomas']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']


abstract: BACKGROUND: @entity4093 ( @entity4093 ) and @entity11935 ( @entity11935 ) are @entity2125 -dependent protein deacetylases involved in the regulation of key @entity5 -associated genes. In this study we evaluated the relevance of these deacetylases in @entity2 biology. MATERIAL AND METHODS: Protein levels of @entity4093 and @entity11935 were determined in @entity1149 ( @entity1149 ) cell lines and @entity5 from 105 @entity1 . Changes in proliferation were assessed after @entity4093 and @entity11935 downregulation in @entity2 cell lines using siRNA-mediated technology or tenovin-1, a @entity4093 and @entity11935 inhibitor. RESULTS: High @entity4093 and @entity11935 protein levels were found in @entity1149 cell lines compared with non-tumor lung epithelial cells. The expression of @entity4093 and @entity11935 proteins was also significantly higher in lung @entity5 than in normal tissue (P<0.001 for both sirtuins). Stronger nuclear @entity4093 staining was observed in @entity420 than in @entity957 (P=0.033). Interestingly, in @entity1149 @entity1 , high @entity4093 and @entity11935 expression levels were associated with shorter recurrence-free survival (P=0.04 and P=0.007, respectively). Moreover, the combination of high @entity4093 and @entity11935 expression was an independent prognostic factor for shorter recurrence-free survival (P=0.002) and overall survival (P=0.022). In vitro studies showed that @entity4093 and/or @entity11935 downregulation significantly decreased proliferation of @entity1149 . CONCLUSIONS: Our results support the hypothesis that @entity4093 and @entity11935 have a protumorigenic role in @entity2 , promoting cell proliferation. Moreover, the expression of these proteins is associated with poor prognosis in @entity1149 @entity1 and may help to identify those @entity1149 @entity1 with high risk of recurrence that could benefit from adjuvant therapy after resection.

title: Expression of sirtuin 1 and 2 is associated with poor prognosis in @entity1149 XXXX .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVE: Genomewide association studies (GWAS) have shown that variation in the @entity5523 ( @entity5523 ) is associated with plasma @entity412 levels but that common variants account for only 1.25% of the variance. The aim of this study was to determine the frequency of rare variants in the @entity5523 gene in @entity1 with various forms of @entity2298 . METHODS: The DNA sequence of the exons plus exon/intron boundaries of the @entity5523 gene of 313 @entity1 with @entity1674 above the 95th percentile for age and sex (107 of whom had @entity1674 above 875 mg/dl) and 121 @entity1 with @entity407 was determined. RESULTS: Twenty rare variants were detected of which seven have been previously reported. All of the rare variants were present as heterozygotes. Sixteen were missense mutations, two were short deletion mutants and there were single nonsense and insertion mutations. Fifteen of the missense mutations resulted in an @entity535 change. There were 13 @entity1 (12.1%) with @entity1674 above 875 mg/dl and 10 @entity1 (4.9%) with moderately elevated @entity1674 , who were carriers of at least one rare, non-synonymous mutation in the @entity5523 gene. Of the @entity1 with @entity21027 , two were carriers of rare variants. CONCLUSION: Rare mutations in the @entity5523 gene are frequent in @entity1 with elevated @entity1674 .

title: Rare variants in the XXXX ( @entity5523 ) gene are common in @entity2298 but rare in @entity407 .

entities_list: @entity2298 :: ('MESH:D015228', 'Disease') :: ['hypertriglyceridemia']

entities_list: @entity407 :: ('MESH:D006949', 'Disease') :: ['Type III hyperlipidemia']

entities_list: @entity21027 :: ('MESH:C538377', 'Disease') :: ['Type III HLP']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity5523 :: ('4023', 'Gene') :: ['LPL', 'lipoprotein lipase gene']

answer: @entity5523 :: (4023,Gene) :: ['lipoprotein lipase']


abstract: OBJECTIVE: Genomewide association studies (GWAS) have shown that variation in the @entity5523 ( @entity5523 ) is associated with plasma @entity412 levels but that common variants account for only 1.25% of the variance. The aim of this study was to determine the frequency of rare variants in the @entity5523 gene in @entity1 with various forms of @entity2298 . METHODS: The DNA sequence of the exons plus exon/intron boundaries of the @entity5523 gene of 313 @entity1 with @entity1674 above the 95th percentile for age and sex (107 of whom had @entity1674 above 875 mg/dl) and 121 @entity1 with @entity407 was determined. RESULTS: Twenty rare variants were detected of which seven have been previously reported. All of the rare variants were present as heterozygotes. Sixteen were missense mutations, two were short deletion mutants and there were single nonsense and insertion mutations. Fifteen of the missense mutations resulted in an @entity535 change. There were 13 @entity1 (12.1%) with @entity1674 above 875 mg/dl and 10 @entity1 (4.9%) with moderately elevated @entity1674 , who were carriers of at least one rare, non-synonymous mutation in the @entity5523 gene. Of the @entity1 with @entity21027 , two were carriers of rare variants. CONCLUSION: Rare mutations in the @entity5523 gene are frequent in @entity1 with elevated @entity1674 .

title: Rare variants in the @entity5523 ( XXXX ) gene are common in @entity2298 but rare in @entity407 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity5523 :: (4023,Gene) :: ['LPL']


abstract: OBJECTIVE: Genomewide association studies (GWAS) have shown that variation in the @entity5523 ( @entity5523 ) is associated with plasma @entity412 levels but that common variants account for only 1.25% of the variance. The aim of this study was to determine the frequency of rare variants in the @entity5523 gene in @entity1 with various forms of @entity2298 . METHODS: The DNA sequence of the exons plus exon/intron boundaries of the @entity5523 gene of 313 @entity1 with @entity1674 above the 95th percentile for age and sex (107 of whom had @entity1674 above 875 mg/dl) and 121 @entity1 with @entity407 was determined. RESULTS: Twenty rare variants were detected of which seven have been previously reported. All of the rare variants were present as heterozygotes. Sixteen were missense mutations, two were short deletion mutants and there were single nonsense and insertion mutations. Fifteen of the missense mutations resulted in an @entity535 change. There were 13 @entity1 (12.1%) with @entity1674 above 875 mg/dl and 10 @entity1 (4.9%) with moderately elevated @entity1674 , who were carriers of at least one rare, non-synonymous mutation in the @entity5523 gene. Of the @entity1 with @entity21027 , two were carriers of rare variants. CONCLUSION: Rare mutations in the @entity5523 gene are frequent in @entity1 with elevated @entity1674 .

title: Rare variants in the @entity5523 ( @entity5523 ) gene are common in XXXX but rare in @entity407 .

answer: @entity2298 :: (MESH:D015228,Disease) :: ['hypertriglyceridemia']


abstract: OBJECTIVE: Genomewide association studies (GWAS) have shown that variation in the @entity5523 ( @entity5523 ) is associated with plasma @entity412 levels but that common variants account for only 1.25% of the variance. The aim of this study was to determine the frequency of rare variants in the @entity5523 gene in @entity1 with various forms of @entity2298 . METHODS: The DNA sequence of the exons plus exon/intron boundaries of the @entity5523 gene of 313 @entity1 with @entity1674 above the 95th percentile for age and sex (107 of whom had @entity1674 above 875 mg/dl) and 121 @entity1 with @entity407 was determined. RESULTS: Twenty rare variants were detected of which seven have been previously reported. All of the rare variants were present as heterozygotes. Sixteen were missense mutations, two were short deletion mutants and there were single nonsense and insertion mutations. Fifteen of the missense mutations resulted in an @entity535 change. There were 13 @entity1 (12.1%) with @entity1674 above 875 mg/dl and 10 @entity1 (4.9%) with moderately elevated @entity1674 , who were carriers of at least one rare, non-synonymous mutation in the @entity5523 gene. Of the @entity1 with @entity21027 , two were carriers of rare variants. CONCLUSION: Rare mutations in the @entity5523 gene are frequent in @entity1 with elevated @entity1674 .

title: Rare variants in the @entity5523 ( @entity5523 ) gene are common in @entity2298 but rare in XXXX .

answer: @entity407 :: (MESH:D006949,Disease) :: ['Type III hyperlipidemia']


abstract: OBJECTIVE: To evaluate the population and economic impact of implementing the new Joint National Committee (JNC) or European Society of @entity101 (ESH)/European Society of Cardiology (ESC) @entity101 guidelines in the Swiss population. METHODS: Cross-sectional, population-based sample (6708 @entity1 ) collected between 2003 and 2006 in the city of Lausanne, Switzerland. Blood pressure categories were defined according to both the JNC (JNC-7 and JNC-8) and the ESH/ESC (2007 and 2013) guidelines. RESULTS: The proportion of @entity1 aged 35-60 years eligible for drug treatment was 25.6% [95% confidence interval (CI) 24.4-26.9%] and 24.8% (95% CI 23.6-26.0%) for the JNC-7 and the JNC-8 guidelines, respectively; for @entity1 aged 60-75 years, the values were 62.3% (95% CI 60.1-64.5%) and 46.8% (95% CI 44.5-49.0%), respectively. Shifting from the JNC-7 to the JNC-8 guidelines would lead to an annual saving of 163.6 million Swiss francs (187.7 million US dollars or 134.5 million European    ). The proportion of @entity1 aged 35-75 years without @entity740 , @entity6 or reported history of @entity65 and eligible for treatment was 30.2% (95% CI 29.0-31.4%) for the ESH/ESC 2007 and 2013 guidelines. For @entity1 with @entity740 , @entity6 or reported history of @entity65 , the values were 73.6% (95% CI 70.8-76.3%) and 55.6% (95% CI 52.5-58.8%), respectively. Shifting from the ESH/ESC 2007 to the ESH/ESC 2013 guidelines would lead to an annual saving of 86.9 million Swiss francs (99.5 million US dollars or 71.4 million European    ). CONCLUSION: In Switzerland, shifting from the JNC-7 to the JNC-8 guidelines or from the ESH/ESC 2007 to the ESH/ESC 2013 guidelines would decrease the prevalence of @entity1 eligible for treatment and increase the percentage of treated @entity1 within blood pressure goals. Both strategies lead to potential savings in antihypertensive drug treatment.

title: Eligibility to treatment and economic effect of the implementation of the new U.S. or European Society of XXXX /European Society of Cardiology @entity101 guidelines.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'Hypertension']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus']

entities_list: @entity740 :: ('MESH:D051436', 'Disease') :: ['chronic kidney disease']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

answer: @entity101 :: (MESH:D006973,Disease) :: ['Hypertension']


abstract: OBJECTIVE: To evaluate the population and economic impact of implementing the new Joint National Committee (JNC) or European Society of @entity101 (ESH)/European Society of Cardiology (ESC) @entity101 guidelines in the Swiss population. METHODS: Cross-sectional, population-based sample (6708 @entity1 ) collected between 2003 and 2006 in the city of Lausanne, Switzerland. Blood pressure categories were defined according to both the JNC (JNC-7 and JNC-8) and the ESH/ESC (2007 and 2013) guidelines. RESULTS: The proportion of @entity1 aged 35-60 years eligible for drug treatment was 25.6% [95% confidence interval (CI) 24.4-26.9%] and 24.8% (95% CI 23.6-26.0%) for the JNC-7 and the JNC-8 guidelines, respectively; for @entity1 aged 60-75 years, the values were 62.3% (95% CI 60.1-64.5%) and 46.8% (95% CI 44.5-49.0%), respectively. Shifting from the JNC-7 to the JNC-8 guidelines would lead to an annual saving of 163.6 million Swiss francs (187.7 million US dollars or 134.5 million European    ). The proportion of @entity1 aged 35-75 years without @entity740 , @entity6 or reported history of @entity65 and eligible for treatment was 30.2% (95% CI 29.0-31.4%) for the ESH/ESC 2007 and 2013 guidelines. For @entity1 with @entity740 , @entity6 or reported history of @entity65 , the values were 73.6% (95% CI 70.8-76.3%) and 55.6% (95% CI 52.5-58.8%), respectively. Shifting from the ESH/ESC 2007 to the ESH/ESC 2013 guidelines would lead to an annual saving of 86.9 million Swiss francs (99.5 million US dollars or 71.4 million European    ). CONCLUSION: In Switzerland, shifting from the JNC-7 to the JNC-8 guidelines or from the ESH/ESC 2007 to the ESH/ESC 2013 guidelines would decrease the prevalence of @entity1 eligible for treatment and increase the percentage of treated @entity1 within blood pressure goals. Both strategies lead to potential savings in antihypertensive drug treatment.

title: Eligibility to treatment and economic effect of the implementation of the new U.S. or European Society of @entity101 /European Society of Cardiology XXXX guidelines.

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertension']


abstract: OBJECTIVE: To assess disability in @entity785 ( @entity785 ) longitudinally and to identify disease-specific determinants, after accounting for informative @entity1 dropout. METHODS: We performed a multicenter, longitudinal study of 745 @entity1 with @entity785 followed in the Canadian @entity2631 Research Group registry. Disability was assessed using the Health Assessment Questionnaire (HAQ). Longitudinal changes in disability were modeled using statistical approaches accounting for various levels of @entity1 dropout. RESULTS: In all the models, disability in @entity785 worsened over time. The magnitude of the worsening was small when @entity1 dropout was assumed to be completely at random (increase in the HAQ of 0.022, 95% CI 0.002-0.042, per year). After accounting for different levels of informative @entity1 dropout, the increase in the HAQ ranged from 0.039 (95% CI 0.018-0.061) per year to 0.071 (95% CI 0.048-0.094) per year. Thus, using the most conservative of these estimates, this was equivalent to an increase in the HAQ of 0.12 over 3 years. The disease correlates found to be most closely associated with disability were @entity66 and breathing problems. CONCLUSION: Our study provides strong evidence that @entity785 causes increased disability over time, with breathing problems and disease type being the strongest predictors of disability. Statistical modeling accounting for informative @entity1 dropout is necessary to properly assess the outcomes of @entity1 followed longitudinally.

title: Disability in XXXX -- a longitudinal observational study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['diffuse disease']

entities_list: @entity2631 :: ('MESH:D012594', 'Disease') :: ['Scleroderma']

entities_list: @entity785 :: ('MESH:D012595', 'Disease') :: ['systemic sclerosis', 'SSc']

answer: @entity785 :: (MESH:D012595,Disease) :: ['systemic sclerosis']


abstract: In this study, @entity137 data of aquatic species in Liaohe River for heavy metal @entity3407 (VI) was collected and selected. The aquatic life criteria for @entity6596 in Liaohe River was derived based on these @entity137 data. Moreover, water samples of 25 sites in Liaohe River were collected, and the concentrations of @entity6596 in these samples were analyzed. Finally, ecological risk assessment of @entity6596 in Liaohe River was performed. Moreover, interspecies correlation estimation method (ICE) established by US EPA was used to predict the acute @entity137 of species in Liaohe River, and aquatic life criteria based on predicted @entity137 data was derived. The results showed that: the measured CMC (criteria maximum concentration), measured CCC (criteria continuous concentration) and the predicted CMC were 17. 73, 12. 15 and 13. 97   g . @entity5022 , respectively. Therefore, the ICE method could be used to predict the aquatic life criteria, because the predicted criteria value was very similar to the measured criteria value. Analysis of @entity3407 (V) showed that the @entity6596 concentrations of the 25 sites in Liaohe River were all below Class I or Class II water quality standards (GB 3838-2002), and the water quality was in good condition. However, for the potential risk of @entity6596 exposure to the aquatic life of Liaohe River, the result of ecological risk assessment showed that @entity3407 (V) concentrations in 7 sites exceeded the CCC in July, and @entity6596 concentrations in 6 sites exceeded the CCC in December. Therefore, unacceptable effect on aquatic species caused by @entity6596 exposure might have occurred in some sites of Liaohe River.

title: [Measured and Predicted Aquatic Life Criteria and Risk Assessment of XXXX (VI) in Liaohe River].

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity3407 :: ('MESH:D002857', 'Chemical') :: ['chromium']

entities_list: @entity6596 :: ('MESH:C074702', 'Chemical') :: ['chromium (VI)']

answer: @entity3407 :: (MESH:D002857,Chemical) :: ['Chromium']


abstract: BACKGROUND: When a @entity1 is diagnosed with @entity2438 , parents are faced with the task of choosing from many different intervention options. To find information about the options available, parents turn to a number of different sources. This study explores parents' (n   =   23) intervention decision-making processes and information preferences following the diagnosis of @entity2438 for their @entity1 . METHODS: Qualitative thematic analysis of verbatim transcripts from interviews and focus groups involving parents of @entity1 with an @entity2438 diagnosis was undertaken. RESULTS: Analysis of the results revealed that there are concurrent emotional and pragmatic intervention 'journeys' undertaken by parents post diagnosis, which encompass the primary themes of: (1) information sources used, (2) parents' information preferences and (3) factors influencing intervention decision making. Parents described a journey from the point of diagnosis that involved seeking information on @entity2438 interventions from multiple sources, with the Internet being the primary source. They were overwhelmed by the sheer volume of information available, and their preferences for information varied according to their stage in the journey post diagnosis. Parents had a 'trial and error' approach to choosing @entity2438 interventions, with confidence increasing as they became more familiar with their @entity1 's condition, and had opportunities to explore numerous information sources about their @entity1 's diagnosis. While confidence increased over time, consideration of the effectiveness or evidence supporting interventions remained largely absent throughout the journey. CONCLUSION: This study highlights the need for parents of @entity1 with @entity2438 to be supported to make informed intervention decisions, particularly with consideration for research evidence.

title: Intervention decision-making processes and information preferences of parents of XXXX with autism spectrum disorders.

entities_list: @entity1 :: ('9606', 'Species') :: ['child', 'children']

answer: @entity1 :: (9606,Species) :: ['children']


abstract: Chemotherapy combinations with monoclonal antibodies are now the basis for treatment of @entity1072 . Rituximab, the most widely used antiCD20 antibody in routine clinical practice, led not only to improvement of progressionfree survival, but also to improvement of overall survival in previously untreated @entity1 with good performance status in combination with @entity3118 and @entity786 . This regimen has become the standard treatment for @entity1 in good physical condition. Rituximab and the newest antiCD20 antibody obinutuzumab in combination with @entity5805 , as compared with @entity5805 alone, prolonged overall survival in previously untreated @entity1 with significant comorbidities, and the combination of antiCD20 antibody with @entity5805 has become the standard regimen in this group of @entity1 . Alemtuzumab and ofatumumab improved treatment results in @entity1072 . Targeted therapy with combination chemotherapy and monoclonal antibody in @entity1 with @entity1072 represents a significant advance in the treatment of this disease.Key words: monoclonal antibody - rituximab - ofatumumab - alemtuzumab - obinutuzumabThis study was supported by the program PRVOUK P27/LF1/1 and grant IGA-LF-2015-001.The authors declare they have no potential conflicts of interest concerning drugs, products, or   services used in the study.The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.Submitted: 28. 7. 2015Accepted: 2. 8. 2015.

title: [Monoclonal Antibodies in the Treatment of XXXX in 2015].

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity1072 :: ('MESH:D015451', 'Disease') :: ['chronic lymphocytic leukemia', 'refractory chronic lymphocytic leukemia']

entities_list: @entity5805 :: ('MESH:D002699', 'Chemical') :: ['chlorambucil']

entities_list: @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine']

answer: @entity1072 :: (MESH:D015451,Disease) :: ['Chronic Lymphocytic Leukemia']


abstract: Among @entity1 in general hospitals approximately one-third receive antimicrobial drugs, and @entity580 develop in 3 to 4 percent of them. These two events vary widely suggesting no constant relation, except that antibiotic use affects the etiology and course of @entity580 . There is deliberation about the benefits versus the harm of antibiotic prophylaxis. It avoids the morbidity and tissue damage from @entity281 with the least antibiotic for the shortest time and works best when the need is brief or the microbial target is a single species. Among nonsurgical @entity1 , a high risk of @entity281 results from exposure to a transmissible @entity281 , minor procedural @entity130 or increased host susceptibility. In clinical use, antimicrobial prophylaxis usually combines inefficiency with unproved efficacy. Prevention of nosocomial acquisition of @entity293 , @entity55 , @entity295 and @entity281 by antibiotic prophylaxis is ineffective. Recommendations in other conditions are derived mostly from presumed benefit, recognized failures and assessment of adverse results from drug use. Inefficient long-term prophylaxis contributes to the emergence of transmissible bacterial drug resistance. Those clinical conditions that represent need with reasonable efficiency and those that are useless and dangerous prophylactic practices should be defined. Using one and avoiding the other through education and professional discipline offers the best hope of amplifying effective antibiotic prophylaxis and minimizing unwanted effects on the recipient and hospital cohorts.

title: Considerations of antibiotic prophylaxis in nonsurgical high risk XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity295 :: ('MESH:D018805', 'Disease') :: ['catheter sepsis']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'cutaneous infections']

entities_list: @entity580 :: ('MESH:D003428', 'Disease') :: ['nosocomial infections']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['urinary tract infection']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVE: To comparatively analyze the efficacy, acceptability, and tolerability of various augmentation agents in adult @entity1 with @entity13217 . DATA SOURCES: An electronic literature search of PubMed, EMBASE, the Cochrane Library, Web of Science, EBSCO, PsycINFO, EAGLE, and NTIS for trials published up to December 2013 was conducted. Several clinical trial registry agencies and US Food and Drug Administration reports were also reviewed. No language, publication date, or publication status restrictions were imposed. STUDY SELECTION: Randomized controlled trials comparing 11 augmentation agents ( @entity1770 , @entity752 , @entity5633 , @entity2812 , @entity1091 , @entity2727 , @entity1037 , @entity7690 , @entity1089 , @entity1090 , and @entity6145 ) with each other and with placebo for adult @entity13217 were included. DATA EXTRACTION: The proportion of @entity1 who responded to treatment was defined as primary efficacy, and the proportion of all-cause discontinuation and side-effects discontinuation were respectively defined as acceptability and tolerability, which were assessed with odds ratios (ORs) and a Bayesian random-effects model with 95% credible intervals (CrIs). RESULTS: A total of 48 trials consisting of 6,654 @entity1 were eligible. In terms of the primary efficacy, @entity1089 (OR = 1.92; 95% CrI, 1.39-3.13), @entity1770 (OR = 1.85; 95% CrI, 1.27-2.27), @entity6145 (OR = 1.84; 95% CrI, 1.06-3.56), and @entity1091 (OR = 1.56; 95% CrI, 1.05-2.55) were significantly more effective than placebo. Sensitivity analyses indicated that efficacy estimates for @entity1770 and @entity1089 were more robust than those for @entity6145 and @entity1091 . In terms of acceptability, no significant difference was found between active agents and placebo. In terms of tolerability, compared to placebo, @entity1089 (OR = 3.85; 95% CrI, 1.92-8.33), @entity1037 (OR = 3.36; 95% CrI, 1.60-8.61), @entity1770 (OR = 2.51; 95% CrI, 1.11-7.69), and @entity1091 (OR = 2.30; 95% CrI, 1.04-6.03) were significantly less well tolerated. CONCLUSIONS: @entity1089 and @entity1770 appear to be the most robust evidence-based options for augmentation therapy in @entity1 with @entity13217 , but clinicians should interpret these findings cautiously in light of the evidence of potential treatment-related side effects.

title: Comparative efficacy, acceptability, and tolerability of augmentation agents in XXXX : systematic review and network meta-analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients']

entities_list: @entity2812 :: ('MESH:C047781', 'Chemical') :: ['lamotrigine']

entities_list: @entity5633 :: ('MESH:D002065', 'Chemical') :: ['buspirone']

entities_list: @entity7690 :: ('MESH:D010869', 'Chemical') :: ['pindolol']

entities_list: @entity13217 :: ('MESH:D061218', 'Disease') :: ['treatment-resistant depression']

entities_list: @entity1089 :: ('MESH:C069541', 'Chemical') :: ['quetiapine', 'Quetiapine']

entities_list: @entity6145 :: ('CHEBI:60311', 'Chemical') :: ['thyroid hormone']

entities_list: @entity752 :: ('MESH:D016642', 'Chemical') :: ['bupropion']

entities_list: @entity1037 :: ('MESH:C076029', 'Chemical') :: ['olanzapine']

entities_list: @entity1770 :: ('MESH:C094645', 'Chemical') :: ['aripiprazole']

entities_list: @entity2727 :: ('MESH:D008774', 'Chemical') :: ['methylphenidate']

entities_list: @entity1090 :: ('MESH:D018967', 'Chemical') :: ['risperidone']

answer: @entity13217 :: (MESH:D061218,Disease) :: ['treatment-resistant depression']


abstract: Various kinds of schiff base metal complexes have been proven to induce apoptosis of @entity5 cells. However, it remains largely unknown whether schiff base @entity219 complexes induce apoptosis in @entity1 @entity5 cells. Here, we synthesized a novel schiff base @entity219 coordination compound (SBZCC) and investigated its effects on the growth, proliferation and apoptosis of @entity1 @entity421 MG-63 cells. A novel SBZCC was synthesized by chemical processes and used to treat MG-63 cells. The cell viability was determined by CCK-8 assay. The cell cycle progression, mitochondrial membrane potential and apoptotic cells were analyzed by flow cytometry. The apoptosis-related proteins levels were determined by immunoblotting. Treatment of MG-63 cells with SBZCC resulted in inhibition of cell proliferation and cell cycle arrest at G1 phase. Moreover, SBZCC significantly reduced the mitochondrial membrane potential and induced apoptosis, accompanied with increased @entity589 / @entity588 and FlasL/Fas expression as well as caspase-3/8/9 cleavage. Our results demonstrated that the synthesized novel SBZCC could inhibit the proliferation and induce apoptosis of MG-63 cells via activating both the mitochondrial and cell death receptor apoptosis pathways, suggesting that SBZCC is a promising agent for the development as anticancer drugs.

title: A novel schiff base XXXX coordination compound inhibits proliferation and induces apoptosis of @entity1 @entity421 cells.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity421 :: ('MESH:D012516', 'Disease') :: ['osteosarcoma']

answer: @entity219 :: (MESH:D015032,Chemical) :: ['zinc']


abstract: Various kinds of schiff base metal complexes have been proven to induce apoptosis of @entity5 cells. However, it remains largely unknown whether schiff base @entity219 complexes induce apoptosis in @entity1 @entity5 cells. Here, we synthesized a novel schiff base @entity219 coordination compound (SBZCC) and investigated its effects on the growth, proliferation and apoptosis of @entity1 @entity421 MG-63 cells. A novel SBZCC was synthesized by chemical processes and used to treat MG-63 cells. The cell viability was determined by CCK-8 assay. The cell cycle progression, mitochondrial membrane potential and apoptotic cells were analyzed by flow cytometry. The apoptosis-related proteins levels were determined by immunoblotting. Treatment of MG-63 cells with SBZCC resulted in inhibition of cell proliferation and cell cycle arrest at G1 phase. Moreover, SBZCC significantly reduced the mitochondrial membrane potential and induced apoptosis, accompanied with increased @entity589 / @entity588 and FlasL/Fas expression as well as caspase-3/8/9 cleavage. Our results demonstrated that the synthesized novel SBZCC could inhibit the proliferation and induce apoptosis of MG-63 cells via activating both the mitochondrial and cell death receptor apoptosis pathways, suggesting that SBZCC is a promising agent for the development as anticancer drugs.

title: A novel schiff base @entity219 coordination compound inhibits proliferation and induces apoptosis of @entity1 XXXX cells.

answer: @entity421 :: (MESH:D012516,Disease) :: ['osteosarcoma']


abstract: Various kinds of schiff base metal complexes have been proven to induce apoptosis of @entity5 cells. However, it remains largely unknown whether schiff base @entity219 complexes induce apoptosis in @entity1 @entity5 cells. Here, we synthesized a novel schiff base @entity219 coordination compound (SBZCC) and investigated its effects on the growth, proliferation and apoptosis of @entity1 @entity421 MG-63 cells. A novel SBZCC was synthesized by chemical processes and used to treat MG-63 cells. The cell viability was determined by CCK-8 assay. The cell cycle progression, mitochondrial membrane potential and apoptotic cells were analyzed by flow cytometry. The apoptosis-related proteins levels were determined by immunoblotting. Treatment of MG-63 cells with SBZCC resulted in inhibition of cell proliferation and cell cycle arrest at G1 phase. Moreover, SBZCC significantly reduced the mitochondrial membrane potential and induced apoptosis, accompanied with increased @entity589 / @entity588 and FlasL/Fas expression as well as caspase-3/8/9 cleavage. Our results demonstrated that the synthesized novel SBZCC could inhibit the proliferation and induce apoptosis of MG-63 cells via activating both the mitochondrial and cell death receptor apoptosis pathways, suggesting that SBZCC is a promising agent for the development as anticancer drugs.

title: A novel schiff base @entity219 coordination compound inhibits proliferation and induces apoptosis of XXXX @entity421 cells.

answer: @entity1 :: (9606,Species) :: ['human']


abstract: OBJECTIVE: To evaluate initial experience with a custom made proximal scalloped stent graft for thoracic endovascular aortic repair (TEVAR) of @entity449 involving the arch. METHODS: Between September 2012 and November 2014, @entity1 presenting with a @entity2334 ( @entity2334 ) with short or angulated neck were selected for treatment by custom made proximal scalloped Relay Plus stent grafts (ABS Bolton Medical, Barcelona, Spain). Prospectively acquired data relating to @entity1 demographics, procedure details, clinical outcomes, and complications were analyzed retrospectively. RESULTS: Ten selected @entity1 (50% male, mean age 77      8 years) were treated using a thoracic custom made Relay Plus stent graft, three of whom underwent additional cervical supra-aortic trunk revascularizations. @entity2334 were fusiform in four cases, saccular in three, and three @entity1 were treated for proximal type I endoleaks after previous standard TEVAR. The graft was landed in zone 2 in 3 cases, in zone 1 in 4 cases, and in zone 0 in 3 cases. The custom made scallop was designed to preserve flow in the left subclavian artery in three @entity1 , in the left common carotid artery in four, and in the innominate artery in three. No proximal @entity1070 occurred and proximal sealing was achieved in all cases, with a technical success rate of 100%. All targeted vessels were patent. During a mean follow up of 12      5 months, no conversion to open surgical repair and no @entity1755 occurred. One @entity1 died post-operatively from @entity583 and one @entity1 suffered a @entity64 with complete recovery. One @entity1 had a distal @entity1070 on the 6 month CT scan and is scheduled for distal extension. No @entity451 , retrograde dissection and no other aortic related complications were recorded. CONCLUSIONS: Proximal scalloped stent grafts appear to be an effective additional tool for TEVAR of @entity2334 when dealing with short or angulated proximal necks.

title: Proximal Scallop in XXXX Repair to Overcome Neck Issues in the Arch.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity449 :: ('MESH:D001014', 'Disease') :: ['aortic aneurysms']

entities_list: @entity451 :: ('MESH:C536857', 'Disease') :: ['paraplegia']

entities_list: @entity1755 :: ('MESH:D001019', 'Disease') :: ['aortic rupture']

entities_list: @entity1070 :: ('MESH:D057867', 'Disease') :: ['type I endoleak']

entities_list: @entity2334 :: ('MESH:D017545', 'Disease') :: ['thoracic aortic aneurysm', 'TAA']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

answer: @entity2334 :: (MESH:D017545,Disease) :: ['Thoracic Endovascular Aortic Aneurysm']


abstract: A very rare, but severe complication, occurring together with @entity1468 , is the so-called @entity2102 (H for haemolysis, EL for elevated liver enzymes and LP for low platelet counts). Perinatal mortality for this syndrome is estimated at 9.5% up to 60%, maternal mortality at 3.5%. We examined retrospectively 11 @entity1 of the last 5 years, presenting not only @entity101 , @entity644 and @entity4 , but also pathologically elevated data concerning transaminases, indirect @entity648 and @entity882 ; the mean value for GI in this group was 7.7 (3-11). Thrombocyte counts showed mean values of 71,000 +/- 28,500. In 9 cases the @entity1 suffered from severe upper @entity490 . Liver enzymes and @entity648 were clearly elevated. Time interval between onset of therapy and delivery was 3 days on the average, the mean gestational age at time of delivery was 34 weeks (27-39), average @entity1 weight amounted to 1,960 g (580-3,700 g). 7 of the 11 @entity1 delivered by Caesarian section (64%); perinatal, respectively neonatal 3 babies died (27%). In two cases one Caesarian section did not produce maternal complications; 3 @entity1 had to undergo a hysterectomy. This syndrome is associated with a very problematic obstetrical situation in respect of differential diagnosis, foetal outcome and the high frequency of postoperative maternal complications.

title: [ @entity2102 : a rare, threatening complication in XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'infant']

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity2102 :: ('MESH:D017359', 'Disease') :: ['HELLP syndrome']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['oedema']

entities_list: @entity648 :: ('MESH:D001663', 'Chemical') :: ['bilirubin']

entities_list: @entity1468 :: ('MESH:D011225', 'Disease') :: ['preeclampsia']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

answer: @entity1468 :: (MESH:D011225,Disease) :: ['pre-eclampsia']


abstract: A very rare, but severe complication, occurring together with @entity1468 , is the so-called @entity2102 (H for haemolysis, EL for elevated liver enzymes and LP for low platelet counts). Perinatal mortality for this syndrome is estimated at 9.5% up to 60%, maternal mortality at 3.5%. We examined retrospectively 11 @entity1 of the last 5 years, presenting not only @entity101 , @entity644 and @entity4 , but also pathologically elevated data concerning transaminases, indirect @entity648 and @entity882 ; the mean value for GI in this group was 7.7 (3-11). Thrombocyte counts showed mean values of 71,000 +/- 28,500. In 9 cases the @entity1 suffered from severe upper @entity490 . Liver enzymes and @entity648 were clearly elevated. Time interval between onset of therapy and delivery was 3 days on the average, the mean gestational age at time of delivery was 34 weeks (27-39), average @entity1 weight amounted to 1,960 g (580-3,700 g). 7 of the 11 @entity1 delivered by Caesarian section (64%); perinatal, respectively neonatal 3 babies died (27%). In two cases one Caesarian section did not produce maternal complications; 3 @entity1 had to undergo a hysterectomy. This syndrome is associated with a very problematic obstetrical situation in respect of differential diagnosis, foetal outcome and the high frequency of postoperative maternal complications.

title: [ XXXX : a rare, threatening complication in @entity1468 ].

answer: @entity2102 :: (MESH:D017359,Disease) :: ['HELLP syndrome']


abstract: The stimulation of @entity228 release by the interrenal tissue of @entity1238 was investigated using an in vitro preparation of the interrenals and a radioimmunoassay for determinations of @entity2819 and @entity1369 in the perifusate. The stimulatory activity of four different areas was tested, the pars distalis, the post- and preoptic hypothalamus, and the cerebrum. It was found that besides the pars distalis, the post- and preoptic hypothalamus exhibit stimulatory activity on the interrenals. No such activity was found in the cerebrum. There was a decrease of activity found from the pars distalis to the postoptic and then to the preoptic part of the hypothalamus. The release of both @entity230 had different sensitivity. @entity1369 release was significantly elevated by all three different tissues, while the increase of the release of @entity2819 was only found significant in the case of stimulation by the pars distalis. The results also make clear that the increase of the release of @entity2819 is less than that of @entity1369 . The ratio of @entity2819 to @entity1369 decreased significantly after stimulation. This points to the fact that the rate of conversion of @entity2819 to @entity1369 (18-hydroxylation) is stimulated more than the production of @entity2819 from @entity1420 .

title: The distribution of interrenal stimulating activity in the brain of XXXX .

entities_list: @entity1238 :: ('8355', 'Species') :: ['Xenopus laevis']

entities_list: @entity1369 :: ('MESH:D000450', 'Chemical') :: ['Aldosterone', 'aldosterone']

entities_list: @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone']

entities_list: @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid']

entities_list: @entity2819 :: ('MESH:D003345', 'Chemical') :: ['corticosterone']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

answer: @entity1238 :: (8355,Species) :: ['Xenopus laevis']


abstract: OBJECTIVES: Work ability may be considered as an important aspect of well-being and health status. One of the most important factors in association with work ability is health-related quality of life (HRQoL). The aim of this study has been to determine the association between work ability, individual characteristics and HRQoL of female workers. MATERIAL AND METHODS: The design of this study has been cross-sectional. The @entity1442 ( @entity1442 ) and Short-Form General Health Survey (SF-12) questionnaires were used to collect data. Three hundred and twenty female workers were selected from food supplier factories in Karaj. One-way analysis of variance, Pearson's correlation analysis, independent sample t-test and multiple linear regression methods were used to analyze data. RESULTS: Mean (M) and standard deviation (SD) of the @entity1442 stood at 35.02 and 5.57, respectively. The categories of the @entity1442 for @entity1 being as follows: 8.8% poor, 62% moderate, 25.4% good and 3.7% excellent. Mean  SD for the physical component summary (PCS) and @entity1032 ( @entity1032 ) of quality of life was 58.84  11.12 and 57.45  9.94, respectively. There was a positive significant association between the PCS and @entity1032 with the @entity1442 (p = 0.0001). Workers with higher education had a better work ability (p = 0.002) and shift-work workers had a worse work ability (p = 0.03). CONCLUSIONS: Work ability of majority of @entity1 was moderate. Considering mean age of studied @entity1 (27.6 years old), this work ability is not satisfactory. Physical and mental components of the HRQoL were the important factors associated with work ability.

title: Quality of life, work ability and other important indicators of XXXX 's occupational health.

entities_list: @entity1442 :: ('MESH:D020178', 'Disease') :: ['WAI', 'work ability index']

entities_list: @entity1032 :: ('MESH:D008607', 'Disease') :: ['mental component summary', 'MCS']

answer: @entity1 :: (9606,Species) :: ['women']


abstract: BACKGROUND: Exercise is a key component of rehabilitation for soft tissue injuries of the shoulder; however its effectiveness remains unclear. OBJECTIVE: Determine the effectiveness of exercise for @entity158 . METHODS: We searched seven databases from 1990 to 2015 for randomized controlled trials (RCTs), cohort and case control studies comparing exercise to other interventions for @entity158 . We critically appraised eligible studies using the Scottish Intercollegiate Guidelines Network (SIGN) criteria. We synthesized findings from scientifically admissible studies using best-evidence synthesis methodology. RESULTS: We retrieved 4853 articles. Eleven RCTs were appraised and five had a low risk of bias. Four studies addressed @entity5818 . One study addressed nonspecific @entity158 . For variable duration @entity5818 : 1) supervised strengthening leads to greater short-term improvement in @entity158 and disability over wait listing; and 2) supervised and home-based strengthening and stretching leads to greater short-term improvement in @entity158 and disability compared to no treatment. For persistent @entity5818 : 1) supervised and home-based strengthening leads to similar outcomes as surgery; and 2) home-based heavy load eccentric training does not add benefits to home-based rotator cuff strengthening and physiotherapy. For variable duration low-grade nonspecific @entity158 , supervised strengthening and stretching leads to similar short-term outcomes as corticosteroid injections or multimodal care. CONCLUSION: The evidence suggests that supervised and home-based progressive shoulder strengthening and stretching are effective for the management of @entity5818 . For low-grade nonspecific @entity158 , supervised strengthening and stretching are equally effective to corticosteroid injections or multimodal care. SYSTEMATIC REVIEW REGISTRATION NUMBER: CRD42013003928.

title: Is exercise effective for the management of XXXX and other soft tissue injuries of the shoulder? A systematic review by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration.

entities_list: @entity5818 :: ('MESH:D019534', 'Disease') :: ['subacromial impingement syndrome']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'shoulder pain']

answer: @entity5818 :: (MESH:D019534,Disease) :: ['subacromial impingement syndrome']


abstract: Chemotherapy is an integral part of modern day treatment regimen but anticancer drugs fail to demarcate between cancerous and normal cells thereby causing severe form of systemic @entity137 . Among which @entity358 is a dreadful complication developed in @entity5 @entity1 upon cyclophosphamide (CP) therapy. @entity66 , @entity82 , and apoptosis are the major patho-mechanisms involved in CP-induced @entity358 . In the present study, we have synthesized Nano-Se, nanotechnology-based new form of elemental selenium which has significantly lower @entity137 and acceptable bioavailability. In order to meet the need of effective drugs against CP-induced adverse effects, nano selenium (Nano-Se) was tested for its possible protective efficacy on CP-induced @entity358 and @entity236 . @entity8769 resulted in @entity2383 which was revealed by massive histopathological changes. @entity651 was associated with oxidative stress/lipid peroxidation as evident by increased in reactive oxygen species, nitric oxide level, and malondialdehyde (MDA) formation with decreased in level of antioxidants such as reduced glutathione, @entity72029 , glutathione peroxidase, superoxide dismutase, and @entity5533 . Furthermore, CP at a dose of 25  mg/kg b.w. increased pulmonary DNA damage ('comet tail') and triggered DNA fragmentation and apoptosis in @entity19 @entity236 . On the other hand, Nano-Se at a dose of 2  mg  Se/kg b.w., significantly inhibited CP-induced DNA damage in bronchoalveolar lavage cells, and decreased the apoptosis and percentage of DNA fragmentation in @entity236 and also antagonized the reduction of the activities of antioxidant enzymes and the increase level of MDA. Thus, our results suggest that Nano-Se in pre- and co-administration may serve as a promising preventive strategy against CP-induced @entity358 .

title: Nano-Se attenuates cyclophosphamide-induced XXXX through modulation of oxidative stress and DNA damage in Swiss albino @entity19 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['Oxidative stress']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity72029 :: ('54486(Tax:10090)', 'Gene') :: ['glutathione-S-transferase']

entities_list: @entity651 :: ('MESH:D055370', 'Disease') :: ['Lung injury']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary toxicity']

entities_list: @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow toxicity', 'bone marrow cells']

entities_list: @entity8769 :: ('MESH:D000435', 'Disease') :: ['CP intoxication']

entities_list: @entity2383 :: ('MESH:D028361', 'Disease') :: ['structural and functional lung impairment']

answer: @entity651 :: (MESH:D055370,Disease) :: ['pulmonary injury']


abstract: Chemotherapy is an integral part of modern day treatment regimen but anticancer drugs fail to demarcate between cancerous and normal cells thereby causing severe form of systemic @entity137 . Among which @entity358 is a dreadful complication developed in @entity5 @entity1 upon cyclophosphamide (CP) therapy. @entity66 , @entity82 , and apoptosis are the major patho-mechanisms involved in CP-induced @entity358 . In the present study, we have synthesized Nano-Se, nanotechnology-based new form of elemental selenium which has significantly lower @entity137 and acceptable bioavailability. In order to meet the need of effective drugs against CP-induced adverse effects, nano selenium (Nano-Se) was tested for its possible protective efficacy on CP-induced @entity358 and @entity236 . @entity8769 resulted in @entity2383 which was revealed by massive histopathological changes. @entity651 was associated with oxidative stress/lipid peroxidation as evident by increased in reactive oxygen species, nitric oxide level, and malondialdehyde (MDA) formation with decreased in level of antioxidants such as reduced glutathione, @entity72029 , glutathione peroxidase, superoxide dismutase, and @entity5533 . Furthermore, CP at a dose of 25  mg/kg b.w. increased pulmonary DNA damage ('comet tail') and triggered DNA fragmentation and apoptosis in @entity19 @entity236 . On the other hand, Nano-Se at a dose of 2  mg  Se/kg b.w., significantly inhibited CP-induced DNA damage in bronchoalveolar lavage cells, and decreased the apoptosis and percentage of DNA fragmentation in @entity236 and also antagonized the reduction of the activities of antioxidant enzymes and the increase level of MDA. Thus, our results suggest that Nano-Se in pre- and co-administration may serve as a promising preventive strategy against CP-induced @entity358 .

title: Nano-Se attenuates cyclophosphamide-induced @entity651 through modulation of oxidative stress and DNA damage in Swiss albino XXXX .

answer: @entity19 :: (10090,Species) :: ['mice']


abstract: @entity1897 caused by incisions on the dorsum of the foot are a common cause of failed foot surgery and can be severely @entity158 and disabling. Thirty-seven @entity1 with 55 symptomatic @entity1897 were evaluated and treated at the Painful Foot Center. Ten @entity1 with moderately severe symptoms chose not to undergo surgery and were treated with oversized shoes with or without protective orthoses. Twenty-seven @entity1 underwent surgery. Four with spindle @entity2950 were treated by neurolysis. Two improved slightly, one remained the same, and one became worse. Twenty-three were treated by proximal resection with or without @entity9 into an appropriate muscle belly. Thirteen of the 23 obtained good results, four obtained fair results, and six obtained poor results. Thus, a total of 20 @entity1 (74%) obtained clinically satisfactory results, and seven (26%), unsatisfactory results. It is much easier to prevent a @entity2950 by meticulous surgical technique than to treat a highly symptomatic @entity2950 .

title: XXXX --leading to failed foot surgery.

entities_list: @entity1897 :: ('MESH:D010523', 'Disease') :: ['sensory nerve neuromas', 'Sensory nerve neuromas']

entities_list: @entity2950 :: ('MESH:D009463', 'Disease') :: ['sensory neuroma', 'neuroma', 'neuromas']

entities_list: @entity9 :: ('MESH:D009437', 'Disease') :: ['burial of the nerve stump']

answer: @entity1897 :: (MESH:D010523,Disease) :: ['Sensory nerve neuromas']


abstract: UNASSIGNED: Our aim was to clarify the perinatal outcomes of and risk factors for @entity101 that is first detected after labor onset (labor onset @entity101 , LOH), which may be a risk factor for @entity3036 and @entity64 during labor. A total of 1349 parturient @entity1 who did not exhibit @entity1468 or gestational @entity101 prior to labor were examined. The @entity1 were classified into four groups: the normotensive (n=1023) (whose systolic blood pressure (SBP) remained below 140   mm   Hg throughout labor), mild LOH (n=241) (whose maximum SBP during labor ranged from 140 to 159   mm   Hg), severe LOH (n=66) (whose maximum SBP during labor ranged from 160 to 179   mm   Hg) and emergent LOH groups (n=19) (whose maximum SBP during labor was greater than 180   mm   Hg). The perinatal outcomes and @entity1 characteristics of the four groups were compared. Twenty-four percent of the pregnant @entity1 who remained normotensive throughout pregnancy developed @entity101 during labor. One of the @entity1 in the emergent LOH group developed @entity3036 . The blood pressure at delivery and frequencies of hypotensor use, interventional delivery and low Apgar scores differed significantly among the four groups. The following risk factors for severe/emergent LOH were extracted: being over 35 years old, a body mass index at delivery of >30, an SBP at 36 weeks' gestation of 130-134   mm   Hg, an SBP at admission of 130-139   mm   Hg, @entity644 (a score of 2+ on the dipstick test) and severe @entity4 . The risk factors for severe/emergent LOH were identified in this study. In high risk cases, repeatedly measuring maternal blood pressure during delivery might help detect critical @entity101 early.

title: The risk factors for labor onset XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient']

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity3036 :: ('MESH:D004461', 'Disease') :: ['eclampsia']

entities_list: @entity1468 :: ('MESH:D011225', 'Disease') :: ['preeclampsia']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertension']


abstract: OBJECTIVE: Histological grade is a well-established prognostic/predictive factor in @entity0 . However, mainly within intermediate categories, @entity1 may have unpredictable outcome. We hypothesised whether ploidy status can distinguish different prognostic groups among @entity0 @entity1 with similar @entity5 grade. MATERIAL AND METHODS: The study involved 684 @entity1 with invasive @entity0 , and median follow-up of 134.5 months. Pathological staging was evaluated according to WHO classification. @entity5 differentiation was assessed using the Nottingham grading system. Ploidy was determined prospectively by DNA flow cytometry. Disease-free survival (DFS) and @entity1349 ( @entity1349 ) were estimated by the Kaplan-Meier method. RESULTS: There were 179 (26.2%) deaths and 239 (33.3%) disease recurrences. For grading, @entity5 were classified as follows: 163 (23.8%) G1, 356 (52.1%) G2 and 165 (24.1%) G3, while 389 (56.9%) @entity5 presented @entity2007 . Ploidy and grading are strongly associated (P  <  0.001). @entity1 with @entity5 showed worse DFS (P  =  0.001) and @entity1349 (P  <  0.001), as well as those with @entity5 in relation to @entity1349 (P  =  0.013). When a subset analysis was performed in early @entity0 @entity1 (n  =  451) with Stage I/IIA of disease, it remained the same significant associations of aneuploid G1 (to @entity1349 ) and G2 @entity5 (to DFS and @entity1349 ) with unfavourable prognosis. CONCLUSIONS: Aneuploidy identifies subsets of @entity0 @entity1 with G1 and G2 @entity5 who showed poor clinical outcome. The finding has therapeutic implications, as these @entity1 are potential candidates to risk-adapted adjuvant therapy.

title: Aneuploidy identifies subsets of @entity1 with poor clinical outcome in  grade 1 and grade 2 XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity2007 :: ('MESH:D000782', 'Disease') :: ['aneuploidy']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast carcinoma', 'breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['aneuploid G1 tumours', 'Tumour', 'tumours', 'aneuploid G2 tumours', 'tumour']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: OBJECTIVE: Histological grade is a well-established prognostic/predictive factor in @entity0 . However, mainly within intermediate categories, @entity1 may have unpredictable outcome. We hypothesised whether ploidy status can distinguish different prognostic groups among @entity0 @entity1 with similar @entity5 grade. MATERIAL AND METHODS: The study involved 684 @entity1 with invasive @entity0 , and median follow-up of 134.5 months. Pathological staging was evaluated according to WHO classification. @entity5 differentiation was assessed using the Nottingham grading system. Ploidy was determined prospectively by DNA flow cytometry. Disease-free survival (DFS) and @entity1349 ( @entity1349 ) were estimated by the Kaplan-Meier method. RESULTS: There were 179 (26.2%) deaths and 239 (33.3%) disease recurrences. For grading, @entity5 were classified as follows: 163 (23.8%) G1, 356 (52.1%) G2 and 165 (24.1%) G3, while 389 (56.9%) @entity5 presented @entity2007 . Ploidy and grading are strongly associated (P  <  0.001). @entity1 with @entity5 showed worse DFS (P  =  0.001) and @entity1349 (P  <  0.001), as well as those with @entity5 in relation to @entity1349 (P  =  0.013). When a subset analysis was performed in early @entity0 @entity1 (n  =  451) with Stage I/IIA of disease, it remained the same significant associations of aneuploid G1 (to @entity1349 ) and G2 @entity5 (to DFS and @entity1349 ) with unfavourable prognosis. CONCLUSIONS: Aneuploidy identifies subsets of @entity0 @entity1 with G1 and G2 @entity5 who showed poor clinical outcome. The finding has therapeutic implications, as these @entity1 are potential candidates to risk-adapted adjuvant therapy.

title: Aneuploidy identifies subsets of XXXX with poor clinical outcome in  grade 1 and grade 2 @entity0 .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: To compare progression-free (PFS) and @entity1349 ( @entity1349 ) in @entity1 treated in two consecutive phase II trials of hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab ( @entity1493 ). @entity1 with newly diagnosed @entity463 ( @entity463 ) after biopsy or resection were enrolled on a clinical trial with hypo-IMRT and TMZ (hypo-IMRT/TMZ alone) from 2008 to 2010, or in the second protocol with the same hypo-IMRT and TMZ plus @entity1493 (hypo-IMRT/TMZ/ @entity1493 ) from 2010 to 2013. All @entity1 received postoperative hypo-IMRT to the surgical @entity5 plus margin to a total dose of 60  Gy and to the T2 abnormality with margin to 30  Gy, both in ten fractions. Concurrent TMZ (75  mg/m(2)/day) was given to all @entity1 for 28 consecutive days followed by adjuvant TMZ (150-200  mg/m(2)/day). @entity1 enrolled on the hypo-IMRT/TMZ/ @entity1493 trial received concurrent and adjuvant @entity1493 (10  mg/kg) on days 1 and 15 of each 28-day cycle. Hazard ratios of PFS and @entity1349 were compared between trials in a Cox proportional hazards model. Twenty-six @entity1 were enrolled on the hypo-IMRT/TMZ alone trial and 30 @entity1 on the hypo-IMRT/TMZ/ @entity1493 trial. Median follow-up was 13.9 and 14.7  months, respectively. Median PFS was 3.4  months longer with hypo-IMRT/TMZ/ @entity1493 but the difference was not statistically significant (12.8 vs. 9.4  months, p  =  0.58). Median ( @entity1349 ) was 16.3  months for both trials. The addition of @entity1493 to TMZ and hypo-IMRT did not improve @entity1349 for @entity1 with @entity463 in two phase II trials with small @entity1 numbers; PFS was longer with @entity1493 , but the difference was not statistically significant.

title: Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab ( XXXX ) for newly diagnosed @entity463 ( @entity463 ): a comparison of two prospective phase II trials.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cavity and residual tumor']

entities_list: @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma multiforme', 'GBM']

answer: @entity1493 :: (12064,Species) :: ['BEV']


abstract: To compare progression-free (PFS) and @entity1349 ( @entity1349 ) in @entity1 treated in two consecutive phase II trials of hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab ( @entity1493 ). @entity1 with newly diagnosed @entity463 ( @entity463 ) after biopsy or resection were enrolled on a clinical trial with hypo-IMRT and TMZ (hypo-IMRT/TMZ alone) from 2008 to 2010, or in the second protocol with the same hypo-IMRT and TMZ plus @entity1493 (hypo-IMRT/TMZ/ @entity1493 ) from 2010 to 2013. All @entity1 received postoperative hypo-IMRT to the surgical @entity5 plus margin to a total dose of 60  Gy and to the T2 abnormality with margin to 30  Gy, both in ten fractions. Concurrent TMZ (75  mg/m(2)/day) was given to all @entity1 for 28 consecutive days followed by adjuvant TMZ (150-200  mg/m(2)/day). @entity1 enrolled on the hypo-IMRT/TMZ/ @entity1493 trial received concurrent and adjuvant @entity1493 (10  mg/kg) on days 1 and 15 of each 28-day cycle. Hazard ratios of PFS and @entity1349 were compared between trials in a Cox proportional hazards model. Twenty-six @entity1 were enrolled on the hypo-IMRT/TMZ alone trial and 30 @entity1 on the hypo-IMRT/TMZ/ @entity1493 trial. Median follow-up was 13.9 and 14.7  months, respectively. Median PFS was 3.4  months longer with hypo-IMRT/TMZ/ @entity1493 but the difference was not statistically significant (12.8 vs. 9.4  months, p  =  0.58). Median ( @entity1349 ) was 16.3  months for both trials. The addition of @entity1493 to TMZ and hypo-IMRT did not improve @entity1349 for @entity1 with @entity463 in two phase II trials with small @entity1 numbers; PFS was longer with @entity1493 , but the difference was not statistically significant.

title: Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab ( @entity1493 ) for newly diagnosed XXXX ( @entity463 ): a comparison of two prospective phase II trials.

answer: @entity463 :: (MESH:D005909,Disease) :: ['glioblastoma multiforme']


abstract: To compare progression-free (PFS) and @entity1349 ( @entity1349 ) in @entity1 treated in two consecutive phase II trials of hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab ( @entity1493 ). @entity1 with newly diagnosed @entity463 ( @entity463 ) after biopsy or resection were enrolled on a clinical trial with hypo-IMRT and TMZ (hypo-IMRT/TMZ alone) from 2008 to 2010, or in the second protocol with the same hypo-IMRT and TMZ plus @entity1493 (hypo-IMRT/TMZ/ @entity1493 ) from 2010 to 2013. All @entity1 received postoperative hypo-IMRT to the surgical @entity5 plus margin to a total dose of 60  Gy and to the T2 abnormality with margin to 30  Gy, both in ten fractions. Concurrent TMZ (75  mg/m(2)/day) was given to all @entity1 for 28 consecutive days followed by adjuvant TMZ (150-200  mg/m(2)/day). @entity1 enrolled on the hypo-IMRT/TMZ/ @entity1493 trial received concurrent and adjuvant @entity1493 (10  mg/kg) on days 1 and 15 of each 28-day cycle. Hazard ratios of PFS and @entity1349 were compared between trials in a Cox proportional hazards model. Twenty-six @entity1 were enrolled on the hypo-IMRT/TMZ alone trial and 30 @entity1 on the hypo-IMRT/TMZ/ @entity1493 trial. Median follow-up was 13.9 and 14.7  months, respectively. Median PFS was 3.4  months longer with hypo-IMRT/TMZ/ @entity1493 but the difference was not statistically significant (12.8 vs. 9.4  months, p  =  0.58). Median ( @entity1349 ) was 16.3  months for both trials. The addition of @entity1493 to TMZ and hypo-IMRT did not improve @entity1349 for @entity1 with @entity463 in two phase II trials with small @entity1 numbers; PFS was longer with @entity1493 , but the difference was not statistically significant.

title: Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab ( @entity1493 ) for newly diagnosed @entity463 ( XXXX ): a comparison of two prospective phase II trials.

answer: @entity463 :: (MESH:D005909,Disease) :: ['GBM']


abstract: BACKGROUND: Psoriasis is a chronic inflammatory disease of the skin with joint manifestations. Greater @entity1569 severity and lower response to treatment have been linked to @entity28 . However, the effect of weight reduction by non-pharmacologic intervention on disease severity is still questionable. This is a systematic review and meta-analysis of @entity23 ( @entity23 ) on the effect of dietary and lifestyle weight loss interventions on @entity1569 severity. METHODS: We comprehensively searched PubMed/MEDLINE, EMBASE and CENTRAL from their inception to August 2014. Inclusion criteria were @entity23 that examined lifestyle intervention by diet or exercise in overweight or @entity28 @entity1 with @entity1569 and measured the severity of @entity1569 as an outcome compared with controls. Two authors independently assessed article quality and extracted the data. RESULTS: Out of 12 full-text articles, 7 @entity23 involving 878 @entity1 met our inclusion criteria. Five of these @entity23 were included in the meta-analysis, which was based on the random-effects model. There was a greater reduction in the Psoriasis Area Severity Index (PASI) score in @entity1 receiving weight loss intervention than in controls, with a pooled mean difference of -2.49 (95% confidence interval (CI), -3.90 to -1.08; P=0.004). More @entity1 in the intervention group than in the control group achieved a 75% reduction in the PASI score, with a pooled odds ratio of 2.92 (95% CI, 1.39-6.13; P=0.005). CONCLUSION: Nonpharmacologic, nonsurgical weight loss intervention is associated with reduction in the severity of @entity1569 in overweight or @entity28 @entity1 . However, more @entity23 with more @entity1 are needed to provide better quality of evidence.

title: Effect of lifestyle weight loss intervention on disease severity in @entity1 with XXXX : a systematic review and meta-analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients']

entities_list: @entity23 :: ('MESH:D007174', 'Disease') :: ['randomized controlled trials', 'RCTs']

entities_list: @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'obesity']

answer: @entity1569 :: (MESH:D011565,Disease) :: ['psoriasis']


abstract: BACKGROUND: Psoriasis is a chronic inflammatory disease of the skin with joint manifestations. Greater @entity1569 severity and lower response to treatment have been linked to @entity28 . However, the effect of weight reduction by non-pharmacologic intervention on disease severity is still questionable. This is a systematic review and meta-analysis of @entity23 ( @entity23 ) on the effect of dietary and lifestyle weight loss interventions on @entity1569 severity. METHODS: We comprehensively searched PubMed/MEDLINE, EMBASE and CENTRAL from their inception to August 2014. Inclusion criteria were @entity23 that examined lifestyle intervention by diet or exercise in overweight or @entity28 @entity1 with @entity1569 and measured the severity of @entity1569 as an outcome compared with controls. Two authors independently assessed article quality and extracted the data. RESULTS: Out of 12 full-text articles, 7 @entity23 involving 878 @entity1 met our inclusion criteria. Five of these @entity23 were included in the meta-analysis, which was based on the random-effects model. There was a greater reduction in the Psoriasis Area Severity Index (PASI) score in @entity1 receiving weight loss intervention than in controls, with a pooled mean difference of -2.49 (95% confidence interval (CI), -3.90 to -1.08; P=0.004). More @entity1 in the intervention group than in the control group achieved a 75% reduction in the PASI score, with a pooled odds ratio of 2.92 (95% CI, 1.39-6.13; P=0.005). CONCLUSION: Nonpharmacologic, nonsurgical weight loss intervention is associated with reduction in the severity of @entity1569 in overweight or @entity28 @entity1 . However, more @entity23 with more @entity1 are needed to provide better quality of evidence.

title: Effect of lifestyle weight loss intervention on disease severity in XXXX with @entity1569 : a systematic review and meta-analysis.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Vasoactive intestinal polypeptide ( @entity38615 )-like material was localised immunohistochemically in the hypothalamus of the @entity1573 hen. Abundant immunoreactive @entity38615 terminals were seen in the external layer of the median eminence and most immunoreactive @entity38615 cell bodies were located in the basal hypothalamus. A few immunoreactive @entity38615 cell bodies and many fibres were found in the preoptic hypothalamus. Intravenous injections of synthetic porcine @entity38615 over a dose range of 12.5 to 100 micrograms kg-1 body wt resulted in dose-related increase in concentration of plasma prolactin in incubating @entity1573 deprived of their nests for 24 hr. These doses of @entity38615 did not stimulate the release of @entity17548 . Studies in vitro showed that synthetic @entity38615 directly stimulated prolactin release from the anterior pituitary gland. The glands from incubating @entity1573 were more responsive to the prolactin-releasing effects of @entity38615 than were the glands from laying birds. Studies in vitro showed that the amount of prolactin released in response to an iv injection of 50 micrograms kg-1 @entity38615 was greater in incubating birds deprived of their nests for 24 hr than in laying hens. Prolactin release was not stimulated in ovariectomized hens after an injection of 50 micrograms kg-1 @entity38615 unless the birds were first treated with @entity2931 or @entity2931 and @entity1420 . It was concluded that a @entity38615 -like material in the @entity1573 hypothalamus may be a physiological prolactin-releasing factor acting at least in part at the level of the anterior pituitary gland.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Evidence that vasoactive intestinal polypeptide is a physiological prolactin-releasing factor in the XXXX hen.

entities_list: @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone']

entities_list: @entity2931 :: ('CHEBI:50114', 'Chemical') :: ['oestrogen']

answer: @entity1573 :: (9031,Species) :: ['bantam']